Industrial Machinery & Robotics Global On demand · 24-48h

Global Automated Cell Counter with Viability Analysis Market Strategic Research Report

Global Automated Cell Counter with Viability Analysis Market…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Automated Cell Counter with Viability Analysis Market
$4402025
9.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Brightfield Imaging, Fluorescence Imaging, Dual-Mode Imaging

By Application: Cell Therapy, Biopharmaceutical Manufacturing, Research Laboratories, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific Inc., Beckman Coulter Life Sciences, Bio-Rad Laboratories, Inc., Logos Biosystems, Inc., ChemoMetec A/S, NanoEnTek Inc., DeNovix Inc., Nexcelom Bioscience LLC (Revvity, Inc.), Merck KGaA, Sartorius AG, Eppendorf SE, ALIT Life Science Co., Ltd., Hangzhou Allsheng Instruments Co., Ltd., Hangzhou Bioer Technology Co., Ltd., Ningbo Scientz Biotechnology Co., Ltd., Shanghai Ruiyu Biotechnology Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 145 pages
Market size 2025
$440
Million USD
Forecast CAGR
9.6%
2025-2032
Forecast 2032
$835.8
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Automated Cell Counter with Viability Analysis market size is predicted to grow from US$ 440 million in 2025 to US$ 829 million in 2032; it is expected to grow at a CAGR of 9.6% from 2026 to 2032.

In 2025, global Automated Cell Counter with Viability Analysis production reached approximately 53.50 k units, with an average global market price of around USD8,000 per unit. The gross profit margin of major manufacturers ranges from 45.00% to 57.00%. In 2025, global production capacity reached approximately 70.39 k units.

An Automated Cell Counter with Viability Analysis is a laboratory instrument designed to rapidly determine cell concentration and cell viability using optical imaging, fluorescence or electrical sensing technologies. It provides accurate and reproducible counting while minimizing manual error and supports suspension cell analysis in research, biopharmaceutical production and clinical laboratories. The product is widely used for cell culture monitoring, quality control and sample preparation but does not replace flow cytometry or advanced cell imaging systems.

The upstream industry includes optical sensors, CMOS cameras, microfluidic chips, electronic components, reagents, disposable counting slides and software. Midstream covers instrument development, assembly, calibration, software integration and quality assurance. Downstream demand mainly comes from pharmaceutical companies, biotechnology firms, hospitals, academic laboratories, cell therapy facilities and contract research organizations. Increasing investment in biologics, regenerative medicine and laboratory automation continues to support market growth.

This report presents a comprehensive overview of the global Automated Cell Counter with Viability Analysis market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Brightfield Imaging
  • Fluorescence Imaging
  • Dual-Mode Imaging

Segment by Sample Format

  • Slide-Based
  • Disposable Chamber-Based
  • Microfluidic Chip-Based

Segment by Cell Concentration Range

  • Below 5×10⁶ cells/mL
  • 5×10⁶–5×10⁷ cells/mL
  • Above 5×10⁷ cells/mL

Segment by Application

  • Cell Therapy
  • Biopharmaceutical Manufacturing
  • Research Laboratories
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Automated Cell Counter with Viability Analysis market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Cell Therapy, Biopharmaceutical Manufacturing, Research Laboratories evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Automated Cell Counter with Viability Analysis Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$440
2025
Forecast
$835.8
2032
CAGR
9.6%
2025–2032
リージョン
5
global
Key companies
Thermo Fisher Scientific Inc.Beckman Coulter Life SciencesBio-Rad Laboratories, Inc.Logos Biosystems, Inc.ChemoMetec A/SNanoEnTek Inc.DeNovix Inc.Nexcelom Bioscience LLC (Revvity
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Brightfield ImagingFluorescence ImagingDual-Mode Imaging
By Application
Cell TherapyBiopharmaceutical ManufacturingResearch LaboratoriesOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Brightfield Imaging
  • 3.1.3 Fluorescence Imaging
  • 3.1.4 Dual-Mode Imaging
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Cell Therapy
  • 4.1.3 Biopharmaceutical Manufacturing
  • 4.1.4 Research Laboratories
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific Inc.
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Beckman Coulter Life Sciences
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Bio-Rad Laboratories, Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Logos Biosystems, Inc.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 ChemoMetec A/S
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 NanoEnTek Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 DeNovix Inc.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Nexcelom Bioscience LLC (Revvity, Inc.)
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Merck KGaA
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Sartorius AG
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Eppendorf SE
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 ALIT Life Science Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Hangzhou Allsheng Instruments Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Hangzhou Bioer Technology Co., Ltd.
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Ningbo Scientz Biotechnology Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Shanghai Ruiyu Biotechnology Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Automated Cell Counter with Viability Analysis market size?
The global Automated Cell Counter with Viability Analysis market is estimated at US$ 440 million in 2025 (base year) and is projected to reach US$ 829 million by 2032.
What growth rate is expected for the Automated Cell Counter with Viability Analysis market through 2032?
The market is expected to grow at a CAGR of 9.6% from 2026 to 2032, expanding from US$ 440 million in 2025 to US$ 829 million in 2032, roughly 1.9 times its base-year value.
How is Automated Cell Counter with Viability Analysis defined?
In 2025, global Automated Cell Counter with Viability Analysis production reached approximately 53.50 k units, with an average global market price of around USD8,000 per unit. The gross profit margin of major manufacturers ranges from 45.00% to 57.00%. In 2025, global production capacity reached approximately 70.39 k units.
How is the Automated Cell Counter with Viability Analysis market segmented by type?
By type, the market is segmented into Brightfield Imaging, Fluorescence Imaging and Dual-Mode Imaging.
What are the key applications of Automated Cell Counter with Viability Analysis?
Key applications covered include Cell Therapy, Biopharmaceutical Manufacturing, Research Laboratories and Other.
Which companies are profiled in the Automated Cell Counter with Viability Analysis market report?
Key players profiled include Thermo Fisher Scientific Inc., Beckman Coulter Life Sciences, Bio-Rad Laboratories, Logos Biosystems, ChemoMetec A/S, NanoEnTek Inc., DeNovix Inc. and Nexcelom Bioscience LLC (Revvity, Inc.), among 16 companies covered in total.
What geographies does the Automated Cell Counter with Viability Analysis market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Automated Cell Counter with Viability Analysis market report?
The report is intended for manufacturers and solution providers, distributors and end users in Cell Therapy, Biopharmaceutical Manufacturing and Research Laboratories, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Automated Cell Counter with Viability Analysis market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.